Myelodysplastic syndromes trials in China

In China 53 Also abroad 368

53 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in China
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Where
Shanghai
Age
18 years to 70 years
People
66
Run by
Ruijin Hospital
See details and how to joinNCT07888348
Phase 1/2Taking people
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
Where
Shanghai
Age
18 years to 70 years
People
60
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07885397
Phase 1Taking people
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Where
Tianjin
Age
18 years and over
People
228
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Beijing
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
Phase 2Taking people
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Where
Beijing
Age
18 years and over
People
40
Run by
Beijing 302 Hospital
See details and how to joinNCT07238686
Phase 1Taking people
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Where
Beijing, Guangdong, Hebei, Hubei
Age
18 years to 75 years
People
168
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06820268
No phaseTaking people
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
Where
Tianjin
Age
18 years to 65 years
People
323
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07578675
Phase 2Taking people
Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT
Where
Beijing
Age
18 years to 65 years
People
120
Run by
Peking University People's Hospital
See details and how to joinNCT07677306
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Lanzhou, Nanchang, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 1Taking people
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Where
Nanchang, Suzhou, Zhengzhou
Age
18 years and over
People
198
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT05641259
No phaseTaking people
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
Where
Hangzhou
Age
12 years to 60 years
People
138
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07183878
Phase 1/2Not yet taking people in China
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
Where
Tianjin
Age
18 years to 75 years
People
92
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07591168
Phase 1Taking people
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Shengyang, Suzhou, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
266 worldwide
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06656494
Phase 1/2Taking people
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Where
Hangzhou
Age
18 years and over
People
29
Run by
Chaser Therapeutics, Inc.
See details and how to joinNCT07761533
No phaseTaking people
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Where
Hainan
Age
18 years to 75 years
People
30
Run by
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
No phaseTaking people
Haplo-Cord HSCT for AML/MDS
Where
Beijing, Chengdu, Fuzhou, Guangzhou
Age
14 years to 60 years
People
82
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT07588360
Phase 2Not yet taking people in China
Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes
Where
Xiamen
Age
60 years and over
People
15
Run by
Zhongshan Hospital (Xiamen), Fudan University
See details and how to joinNCT07616336
Phase 2Taking people
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Where
Shanghai
Age
18 years and over
People
20
Run by
Ruijin Hospital
See details and how to joinNCT07607418
Phase 2Taking people
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
Where
Suzhou
Age
18 years to 65 years
People
66
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07400341
No phaseTaking people
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Where
Suzhou
Age
50 years and over
People
30
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07500753
Phase 1/2Taking people
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Where
Shenzhen
Age
18 years to 75 years
People
96
Run by
Beijing Biotech
See details and how to joinNCT07523555
Phase 2Not yet taking people in China
IFN-α in Relapse Prevention.
Where
Beijing
Age
12 years to 65 years
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07449286
Phase 2Taking people
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Where
Hangzhou
Age
18 years to 75 years
People
63
Run by
Kind Pharmaceuticals LLC
See details and how to joinNCT06304103
No phaseTaking people
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Where
Beijing, Wuhan, Zhengzhou
Age
15 years to 70 years
People
163
Run by
Peking University People's Hospital
See details and how to joinNCT06569095